Semin Respir Crit Care Med 1999; 20(2): 169-178
DOI: 10.1055/s-2007-1009457
Copyright © 1999 by Thieme Medical Publishers, Inc.

The Lung in Systemic Lupus Erythematosus

Joao de Andrade, John I. Kennedy Jr. 
  • Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
Further Information

Publication History

Publication Date:
20 March 2008 (online)

Abstract

Systemic lupus erythematosus (SLE) is a complex systemic disease associated with autoantibody production, immune-complex formation, and alterations in cellular immunity that can affect multiple organs. Respiratory system abnormalities may occur as a direct result of SLE-induced injury (e.g., lupus pneumonitis, microangiitis with alveolar hemorrhage), or more commonly, as a secondary manifestation of the immunosuppressed state. It is imperative to exclude infection and other secondary problems in patients with SLE who present with pleuro-pulmonary disease. High-dose corticosteroids are the mainstay of treatment for most patients with primary pulmonary complications of SLE, with other immunosuppressive agents being reserved for refractory cases.

    >